Neurofibromatoses Therapeutics Competitive Landscape Report 2024: Pipeline Holds 35 Molecules - Currently Only 1 Approved Innovator Drug, AstraZeneca's (Koselugo/Coselugo) Selumetinib Sulfate
Portfolio Pulse from
The competitive landscape for Neurofibromatoses therapeutics is evolving, with 35 molecules in the pipeline and AstraZeneca's Selumetinib Sulfate as the only approved innovator drug. The report anticipates over 986,000 diagnosed cases in 2024 across 16 countries.
February 28, 2025 | 12:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AstraZeneca's Selumetinib Sulfate is currently the only approved drug for Neurofibromatoses, amidst a competitive pipeline of 35 molecules. This positions AstraZeneca strongly in the market.
AstraZeneca's Selumetinib is the only approved drug in a market with a growing number of pipeline candidates. This exclusivity provides a competitive advantage and potential for increased market share as the number of diagnosed cases rises.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80